Richard Bogan to Sodium Oxybate
This is a "connection" page, showing publications Richard Bogan has written about Sodium Oxybate.
Connection Strength
4.221
-
Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers. Sleep Med. 2022 Dec; 100:442-447.
Score: 0.798
-
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022 01; 21(1):53-65.
Score: 0.759
-
Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021 03 12; 44(3).
Score: 0.717
-
Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med. 2020 04; 68:97-109.
Score: 0.647
-
Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. J Clin Sleep Med. 2015 Apr 15; 11(4):427-32.
Score: 0.476
-
Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med. 2009 Jun; 10(6):661-3.
Score: 0.306
-
Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications. CNS Drugs. 2022 06; 36(6):633-647.
Score: 0.195
-
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial. CNS Drugs. 2022 04; 36(4):377-387.
Score: 0.193
-
Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016 08; 24:57-62.
Score: 0.131